Get the Stockscreener App
1.60
6.43%
-0.11
Metavia Inc stock is traded at $1.60, with a volume of 179.77K.
It is down -6.43% in the last 24 hours and up +44.14% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
179.77K
Relative Volume:
0.05
Market Cap:
$8.26M
Revenue:
-
Net Income/Loss:
$-13.13M
P/E Ratio:
-0.2658
EPS:
-6.0188
Net Cash Flow:
$-15.15M
1W Performance:
-20.40%
1M Performance:
+44.14%
6M Performance:
-80.72%
1Y Performance:
-79.22%
1-Day Range:
$1.57
$1.71
1-Week Range:
$1.57
$2.17
52-Week Range:
$0.9661
$19.03
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.60 | 8.26M | 0 | -13.13M | -15.15M | -6.0188 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
Daily Brief Health Care: Viyash Scientific, Guangdong True Health Medical Technology Development, Island Pharmaceuticals , MetaVia and more - Smartkarma
Daily Brief United States: Boston Dynamics, SpaceX, Bloom Energy Corp, Life Time Group Holdings, Maison Solutions, CTW Cayman, Invesco S&P 500 Momentum ETF, MetaVia, Viomi Technology Co Ltd and more - Smartkarma
MetaVia Inc (MTVA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions - Smartkarma
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PR Newswire
MetaVia Inc (MTVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MetaVia Inc (MTVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MTVA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - newsline.com
MetaVia Inc (MTVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MTVA Technical Analysis & ETF Price Forecast - Intellectia AI
MTVA: DA-1726 and vanoglipol show strong clinical and combination potential, with solid cash runway - TradingView
MTVA: Combination therapies show significant weight loss and metabolic benefits; trials fully funded - TradingView
MetaVia Inc. (MTVA) Surges Over 9%: Key Levels to Watch After Strong MoveSwing Trade Setups - newsline.com
MetaVia Shareholders Approve Equity Plan and Reverse Split - The Globe and Mail
MetaVia Company Profile & Introduction - Moomoo
H.C. Wainwright Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Get insights into the top gainers and losers of Tuesday's pre-market session. - ChartMill
MetaVia (MTVA) director awarded 17,186 RSUs vesting in 2027 - Stock Titan
MetaVia (MTVA) awards 17,186 stock units to board director - Stock Titan
MetaVia (MTVA) director gets 17,186 RSUs vesting in 2027 - Stock Titan
MetaVia (MTVA) director Jason Groves awarded 17,186 RSUs in equity grant - Stock Titan
MetaVia (MTVA) director Andrew Koven receives 17,186 deferred RSU grant - Stock Titan
MetaVia Inc. (MTVA) director receives 17,186-share restricted stock grant - Stock Titan
According to documents submitted to the U.S. Securities and Exchange Commission, shareholders of MetaVia Inc have approved a reverse stock split plan, with the specific ratio to be determined within the range of 1-for-5 to 1-for-22. - Bitget
MetaVia (NASDAQ: MTVA) investors back reverse split and equity plan changes - Stock Titan
MetaVia presents promising obesity and metabolic data at ADA 2026 - grafa.com
MTVA: All five business proposals, including a reverse stock split, were approved by shareholders - TradingView
MTVA: All five proposals, including director elections and a reverse stock split, were approved - TradingView
MetaVia Presents Promising DA-1726 and Vanoglipel Combination Data for Obesity and Metabolic Disease at ADA 2026 Sessions - Minichart
MetaVia highlights obesity and metabolic pipeline advancements - TipRanks
MetaVia (NASDAQ: MTVA) posts DA-1726 and vanoglipel obesity, MASH data - Stock Titan
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential - Lelezard
MetaVia reports obesity drug data at diabetes conference By Investing.com - Investing.com Canada
MetaVia's DA-1726 shows 9.1% weight loss at Day... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
MetaVia reports obesity drug data at diabetes conference - Investing.com
MTVA Stock Price and Chart — NASDAQ:MTVA - TradingView
MTVA Soars As MetaVia Cardiometabolic Data Heads To ADA 2026 - StocksToTrade
MTVA Soars As MetaVia’s Diabetes Data Triggers Volatile Surge - StocksToTrade
MetaVia (MTVA) Soars On ADA 2026 Cardiometabolic Breakthrough Buzz - timothysykes.com
Hear MetaVia discuss new obesity and metabolic therapies at June 11 webcast - Stock Titan
MetaVia Stock Slips Again Before a Big Obesity-Drug Week - Bez Kabli
Why MetaVia Stock Is Surging On Friday? - MSN
MSN Money - MSN
MetaVia Inc. (MTVA) Sheds Over 8% as Shares Approach Key SupportSynthetic Short - The Legal Advocate
H.C. Wainwright Maintains MetaVia(MTVA.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726 - Yahoo Finance
MetaVia reports phase 1 data for obesity drug DA-1726 - Investing.com UK
Metavia Inc MTVA-Q Earnings - The Globe and Mail
MetaVia highlights promising Phase 1 obesity drug data - TipRanks
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):